Thromboxane A2 receptor is highly expressed in mouse immature thymocytes and mediates DNA fragmentation and apoptosis by unknown
Bries Definitive Report 
Thromboxane  A2 Receptor Is Highly Expressed in 
Mouse  Immature  Thymocytes  and Mediates  DNA 
Fragmentation  and Apoptosis 
By Fumitaka Ushikubi, Yu-Ichi Aiba,* Ken-Ichi Nakamura, 
Tsunehisa Namba, Masakazu Hirata, Osam Mazda,* 
Yoshimoto Katsura,* and Shuh Narumiya 
From the Department of Pharmacology, Kyoto University Faculty of Medicin6 and the 
*Department of Immunology, Chest Disease Research Institute, Kyoto University, Sakyo-ku, 
Kyoto 606, Japan 
Summary 
We have recently revealed that the thymus is the organ showing the highest expression  of 
thromboxane (TX) A2 receptor in mice. In this study, thymic cell populations expressing the 
receptor were identified, and the effects  of a  TXAz  agonist on these ceUs were examined. 
Radioligand binding using a TXAz receptor-specific radioligand revealed a single class of binding 
sites in the thymocytes with an at~inity and specificity identical to those reported for the TXAu 
receptor. The receptor density in these cells was comparable to that seen in blood platdets. This 
receptor is most highly expressed in CD4-8-  and CD4+8 + immature thymocytes, followed 
by CD4 +8- and CD4-8 + cells. The receptor density in splenic T cells was less than one fifth 
of that in CD4 +  8 + cells and no binding activity was detectable in splenic B cells. The addition 
of a TXA~ agonist, STA2, to thymocytes induced the disappearance  of the CD4+8 + calls in 
a time- and concentration-dependent manner and caused DNA fragmentation. These changes 
were blocked by a  specific TXA2 antagonist,  S-145.  These results demonstrate that TXA2 
induces apoptotic cell death in immature thymocytes by acting on the TXAa receptor on their 
cell  surface  and suggest a role for the TXA2/TXA2 receptor system  in  the thymic micro- 
environment. 
p rostanoids such as prostaglandins (PGs),  thromboxane 
(TX), and leukotrienes (LTs) are a family of oxygenated 
arachidomte metabolites that exit a variety of actions to main- 
tain local homeostasis in the body (1, 2).  Their actions as 
inflammatory mediators are well known; for example, PGE2 
causes vasodilation to increase local blood flow, LTB4 induces 
chemotaxis and activates neutrophils, and LTC4 increases vas- 
cular permeability. Some of these compounds are produced 
upon immunologic  challenge and are mediators of anaphylaxis. 
A recent report also suggests the participation of PGE2 to 
the apoptotic cell death of ovarian surface epithelial calls (3). 
However, little is known about their action in the thymus. 
TXA~ is a very unstable arachidonate metabolite with a half 
life of about 30 s under physiological conditions. Yet, it is 
a potent stimulator of platelets and a constrictor of vascular 
and respiratory smooth muscles,  and is presumed to play a 
role in thrombosis, myocardial infarction, and bronchial asthma 
(4). This compound is synthesized by a specific enzyme, TX 
synthase,  and functions through a cell surface receptor.  We 
have cloned cDNAs for the human and mouse TXA2 recep- 
tors and revealed that they bdong to the family of rhodopsin- 
type receptors (5, 6). Northern blot analysis in various mouse 
organs  showed that  the TXAz  receptor mRNA is  most 
abundantly expressed in the thymus, followed by the spleen 
and lung (6). On the other hand, TX synthase is richest in 
platdets, foUowed by macrophages (7). In the thymus, it is 
present in the cortical epithdial cells and dendritic cells of 
the medulla (8, 9). These findings urged us to investigate 
the localization of the TXAz receptor and its possible role 
in the thymus. In this study, using a radioligand binding assay, 
we determined the distribution of the TXAz  receptor in 
cells of the murine thymus and spleen, and found that this 
receptor is predominantly expressed in immature CD4-8- 
and CD4+8 + thymocytes. We further found that a TXA2 
agonist evokes DNA fragmentation and apoptosis in these cells. 
Materials and Methods 
Materials.  5Z-7-(3-endo-phenylsulphonylamino-bicyclo[2.2.1] 
hept-2-exo-yl) heptenoic  add (S-145)  and [~H]S-145 were gifts from 
Shionogi Research Laboratories (Osaka, Japan). 9,11-epithio-ll,12- 
methano-thromboxone A2 (STA2), 9,11-dimethylmethano-11,12- 
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20-pentanor-15-epi-thromboxane A2 (ONO3708), PGD2, PGF~, 
PGE2, and TXB2 were gifts from Ono Pharmaceuticals (Osaka, 
Japan).  15(S)-hydroxy-ll,9-epoxymethano-prosta-5Z,13E-dienoic 
acid (U46619) and iloprost were obtained from the Upjohn Com- 
pany (Kalamazoo, MI) and Amersham International (Amersham, 
England), respectively. Phycoerythrin-conjugated anti-CD4  and 
fluorescein isothiocyanate-conjugated  anti-CD8 mAbs were pur- 
chased from Becton Dickinson & Co.  (Mountain View, CA). 
Diphenylamine  was purchased  from Sigma Chemical  Co. (St. Louis, 
MO).  All other chemicals used were of reagent grade. 
Cell Preparation and Culture.  BALB/c  mice of 5-7 wk-of-age 
were purchased from Japan SLC, Inc. (Shizuoka, Japan) and used 
after at least 1 wk of maintenance in our laboratory. Thymocyte 
suspensions were prepared in Eagle's  MEM by mincing the thymus 
and filtering dissociated  cells through a nylon mesh (pore size, 40 
#m) (I0). To examine the distribution of the TXA2 receptor, the 
cells were initially treated with either anti-CD4 or anti-CD8 Ab 
or both followed  by treatment with rabbit complement, and sepa- 
rated into fractions of CD4-8 + plus CD4-8- cells, CD4"8 - cells 
plus CD 4-8- cells, and CD4-8- cells (11). Splenic  T cells were 
obtained by passing dissociated cells successively  through a nylon 
wool column and a Sephadex G-10 column. Splenic B ceils were 
obtained as reported previously (11). The purity of the splenic cell 
fractions was  in  the range  of 95-99%.  In  some experiments, 
CD4+8 + cells were sorted using a cell sorter (ABCAS-100; Showa 
Denko Co. Ltd., Tokyo, Japan). 
Binding Assay.  Cells,  washed once with phosphate buffer (10 
mM sodium phosphate, pH 7.4, containing 10 mM EDTA, 5 mM 
KCI, and 135 mM NaCI), were suspended  in Hepes-saline (20 mM 
Hepes, 5 mM KC1, 5 mM MgCI2, and 140 mM NaC1, pH 7.4) 
and the binding assay  was carried out as reported previously (12). 
Ceils were incubated with various concentrations (0.5-8 nM) of 
[3H]S-145 for Scatchard analysis,  or with 5 nM [3H]S-145 and var- 
ious concentrations of TXA2 analogs and PGs in the displacement 
experiments. Nonspecific  binding was determined as the binding 
in the presence of 20/~M  unlabeled S-145. 
DNA  Fragmentation.  Thymocytes were  washed once with 
Eagle's MEM and suspended at 1.8-5.3  ￿  107 cells/ml in RPMI 
1640 containing 1% BSA. The cells were then incubated at 37~ 
in a humidified atmosphere of 5% CO2 in the presence of rele- 
vant agents for 20 h. DNA fragmentation was measured as de- 
scribed by WyUie  (13). Briefly,  the cells  were lysed  with 0.5% Triton 
X-100, and centrifuged at 27,000 g to separate fragmented DNA 
in the supematant from chromatin in the pellet. DNA in the su- 
pernatant and pellet was then precipitated by the addition of tri- 
chloroacetic acid and quantified using the diphenylamine reaction 
(14). The percent fragmentation indicates the ratio of DNA in the 
supernatant to the total DNA recovered in the supematant and 
pellet. The values  are presented after subtracting DNA fragmenta- 
tion in the control experiment, which was 10-15% on average. 
Flow Cytometry.  Thymocytes  were incubated at 37~  in ILPMI 
1640 containing 10% FCS with or without relevant agents for the 
indicated periods. The  cells were stained with phycoerythrin- 
conjugated anti-CD4  and fluorescein isothiocyanate-conjugated 
anti-CD8 mAbs. Approximately 5  x  10  + cells were analyzed by 
a FACScan  |  two-color flow cytometer (Becton Dickinson & Co.) 
as reported previously (10, 11). 
Results  and  Discussion 
The  TXA2  Receptor  Is  Highly  Expressed  in  Immature 
Thymocytes.  A thymocyte suspension was prepared from 5-7- 
wk-old BALB/c mice and used in the binding assay for the 
TXA2 receptor employing [3H]S-145 as a radioligand (12, 
15). Scatchard  analysis of the results showed a single class 
of binding sites with Kd and Bm~, values of 2.03  _+  0.15 nM 
and 788  +_  15 fmol/10  s ceils ('~4,800 sites/cell), respectively 
(Mean  +_  SEM, n  =  4) (Fig.  1 a). This [3H]S-145 binding 
was effectively displaced by TXA2 antagonists and agonists 
with a rank order of potency of S-145>ONO3708>STA2> 
U46619.  The  binding was  partially displaced by  a  PGI2 
agonist, iloprost, and PGD2, while TXB2, PGE2, and PGF2~ 
were ineffective at concentrations up to 10 #M (Fig.  1 b). 
The affinity and specifidty of binding were identical to respec- 
tive values reported for the TXA: receptor in other ceils (12, 
15-17).  These results indicated that  this binding activity 
represents  the TXA2 receptor,  and that the thymocytes ex- 
press this receptor at a density comparable to that found in 
blood platelets,  ~2,000 sites/ceil (18, 19). By incubation in 
buffer alone or with anti-CD4 Ab, anti-CD8 Ab, or both 
Abs, the thymocytes were fractionated into four fractions ac- 
cording to their expression  of CD4 and CD8  (11). A  cell 
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Figure  1.  Binding  of a TXA2 receptor-specific  radioligand,  [3H]S-145, 
to mouse  thymocytes.  (a) Scatchard  analysis.  (b) Specificity  of [3H]S-145 
binding to thymoeytes.  A whole thymocyte  suspension  was prepared and 
ligand binding was carried out as described in Materials and Methods. 
Displacement curves are  shown for various compounds; S-145 (O), 
ONO3708 (0), STA2 (A), U46619 (A), lloprost (D), PGD2 (11), PGF~ 
(~), PGE2 (~7), and TXB2 (V). Mean values (n  z  3) are shown. 
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(11). These ceU fractions were then used in the binding assay 
and the density of the TXA2 receptor in each lymphocyte 
population was calculated.  As shown in Table 1, CD4-8- 
and  CD4+8 +  tbymocytes  expressed  the  highest  level  of 
receptor,  which  was  about  twice  that  of CD4+8 -  and 
CD4-8 + cells and more than  five times that  of splenic T 
cells.  The TXA2 receptor was not detected in B cells with 
the method used. These resuks clearly show that the TXA2 
receptor is expressed early in development of T  cells in the 
thymus and its expression decreases gradually during matu- 
ration.  It is not clear from these results, however, whether 
the receptor is expressed in aU CD4-8-  and CD4 +  8 + cells 
or localized to some subpopulation(s)  of these cells. 
A  TXA2  Agonist,  STA2,  Induces DNA  Fragmentation  in 
Tkymocytes  and a  TXA2 Antagonist,  S-145,  Inkibits this Ac- 
tion.  The preceding results suggest that TXA~ can act on 
thymocytes and induce some biological response.  TXA2 is 
known to evoke phosphatidyl inositol breakdown through 
a GTP binding protein and to induce a rise in the intracel- 
lular Ca  2  + concentration  and activate protein kinase C  (20, 
21). Because several reports (13, 22-24) implicated a rise in 
Ca  2+  concentration  and/or  protein  kinase  C  activation  in 
DNA fragmentation and apoptosis of immature thymocytes, 
we added a TXA2 agonist, STA2 (18, 25), to thymocytes and 
examined  its  effects.  As  shown in  Fig.  2 a,  STA2 induced 
DNA  fragmentation  of  thymocytes  in  a  concentration- 
dependent manner in 20 h of incubation. This effect was half 
maximal at ,,o0.7/zM STA2 and reached a plateau at 10/zM, 
the concentration at which 15% of the total DNA was flag- 
Table  1.  Binding of [JH]S-14S to Lympkocyte Populations of 
Mouse Thymus and Spleen 
b 
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Figure  2.  Induction  of DNA  fragmentation  by  a  specific  TXA2 
agonist, STA2. (a) A concentration-effect curve. Mean  _+ SEM are shown 
(n  =  4).  (b) Inhibition by a specific TXA2 antagonist,  S-145. Mean  _+ 
SEM are shown (n  =  3). 
Organ  Population  [3H]S-145 Binding 
fraol/lO  8 cells* 
Thymus*  Whole T  cells  788  _+  15 
CD4-8-  cdls  934  _+  167 
CD4+8 + ceils  1178  _+  74 
CD4+8 -  ceils  481  +  52 
CD4-8 § cells  404  _+ 38 
Spleen  T  cells  174  _+  15 
B ceils  <60 
* Lymphocytes were prepared  from mouse thymus and separated  into 
fractions of CD4-8 + plus CD4-8- cells, CD4+8 -  plus CD4-8- cells, 
and CD4-8- cells as described in Materials and Methods.  A [3H]S-145 
binding study was carded out in these fractions and unfractionated  cell 
suspensions.  Proportions  of the CD4-8-,  CD4+8 +,  CD4-8 +,  and 
CD4+8 -  cells in these  fractions  were determined by flow cytometric 
analysis using anti-CD4 and anti-CD8 mAbs. The binding activity in 
each cell population  was then calculated from binding values in the above 
fractions  on the basis of their proportions. 
* Mean  +  SEM are shown (n  ~  3-4). 
mented.  Under this condition,  the cell viability, examined 
by  the  trypan  blue  dye  exclusion  method,  decreased  to 
81.6  _+  1.3%  compared with 98.5  +  1.1% in the control 
(mean  _+  SEM, n  =  13). This dose-dependency correlated 
well with that observed for platelet aggregation to STA2 in 
platelet rich plasma (18). The STA2-induced  DNA fragmen- 
tation was inhibited  in  a concentration-dependent  manner 
by a specific  TXA2 antagonist,  S-145  (26) (Fig.  2 b),  sug- 
gesting that it was a receptor-mediated process. Actinomycin 
D, 2 #g/ml, completely inhibited the STA2-induced  increase 
in DNA fragmentation,  suggesting the involvement of pro- 
tein synthesis in this process as reported for steroid-induced 
DNA fragmentation (27). An inactive metabolite of TXA2, 
TXB2,  did  not  induce  DNA  fragmentation.  Some other 
prostaglandins,  PGD2 and PGF~ at 3 #M concentration had 
no effect, whereas PGE2 induced DNA fragmentation com- 
parable  to  that  seen  with  STA2; 16%  fragmentation  at  3 
#M.  Because the  affinity of PGE2  for the TXA2 receptor 
was very low (Fig.  1 b), it probably acted on other types of 
PG receptors. We have recently cloned cDNAs for the EP2 
and EP3 subtypes of the PGEz receptor, and found significant 
expression of their mRNAs in the mouse thymus (28, 29). 
1827  Ushikubi et al.  Brief Definitive Report Contrary  to the effect on thymocytes, STA2 could not in- 
duce DNA fragmentation in splenic T cells (data not shown). 
STA2  Causes Apoptosis in  CD4+8 +  Thymocytes.  The 
above results clearly showed that a TXA2 agonist acted on 
a specific receptor and induced DNA fragmentation and cell 
death in thymocytes. To identify the thymocyte subpopula- 
tions affected by this treatment,  we carried out flow cyto- 
metric analysis using anti-CD4 and anti-CD8 antibodies. As 
shown in Fig. 3 a, this analysis revealed that the proportion 
of viable CD4 +  8 + cells was preferentially decreased by STA2 
treatment, while the proportions of CD4 +  8- and CD4- 8 + 
cells  increased.  S-145  significantly  inhibited  the  STA2-in- 
duced  decrease in  the  CD4+8 +  cell population  (data  not 
shown). The effects of the STA2 on the CD4- 8 -  cells could 
not be determined due to their small numbers. A similar anal- 
ysis was then performed on a cell population containing dead 
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Figure 3.  Flow  cytometric analyses of mouse thymocyte  populations 
after treatment with a specific TXA2 agonist, STA2. (a) and (b) Whole 
thymocytes  were  incubated for 48 h, stained with fluorescence-hbeled  anti- 
CD4 and anti-CD8 antibodies, and analyzed by a FACScan  |  two-color 
flow cytometer as described  in Materials and Methods. The numbers in 
the figures represent the percentage of cells included in each quadrant. 
0 h, cells  before  incubation. 48 h (-STA2) and 48 h (+ STAz), cells treated 
without or with STA2 for 48 h, respectively.  Only viable  cells (a) or both 
viable and dead cells (b) were gated by forward and side-scatter. (c) Anal- 
ysis on an isolated CD4*8 + cell population. CD4+8 + cells were sorted 
with a cell sorter and incubated with or without 10/~M STA2 for 72 h, 
and stained as described. Only viable cells were gated for analysis. 
cells, since Swat et al. (30) recently reported that the expres- 
sion of CD4 and CD8 molecules on the CD4 +  8 + cells was 
reduced during apoptosis and that this change could be de- 
tected when dead cells were included in the analysis.  There- 
fore, we examined whether a similar change occurred during 
STA2 treatment.  As  shown  in  Fig.  3  b,  upon  culturing 
thymocytes in suspension, a distinct subpopulation with de- 
creased expression of CD4 and CD8 molecules appeared in 
a time-dependent manner in the CD4+8 + population,  and 
this subpopulation was increased significantly by the addi- 
tion  of STAz.  These  results  indicated  that  STA2 induced 
apoptosis in CD4 +  8 + cells. To confirm this, we isolated the 
CD4 +  8 + cells by cell sorting and tested the effect of STA2. 
As shown in Fig. 3 c, when viable cells were analyzed, the 
addition  of 10/~M  STA2 accelerated  the  disappearance  of 
double-positive cells. These results strongly suggest that only 
immature CD4+8 + thymocytes are sensitive to TXA2, and 
they undergo apoptosis on exposure to the agonist.  On the 
other hand,  CD4*8 -  and CD4-8 + cells did not undergo 
apoptosis, although they express significant amounts of the 
TXA2 receptor.  A  similar difference in sensitivity between 
immature  and mature thymoeytes has been reported in re- 
sponse to anti-CD3 Ab stimulation (23) and this may be due 
to the presence of a system preventing apoptosis such as kl-2 
gene product  (31,  32) in the mature cells. 
The thymic microenvironment is thought to be very im- 
portant  for T  cell development.  It is presumed to provide 
cell to cell interactions and soluble factors to pursue matura- 
tion and selection of T  cells.  However, neither cell interac- 
tions nor soluble factors responsible for these processes have 
been fully characterized or identified. In this study we found 
that  the  TXA2  receptor  is highly  expressed  in  immature 
thymocytes  and  mediates  the  apoptosis  of these  cells.  As 
demonstrated  by  immunohistochemistry,  TX  synthase  is 
present in reticular epithelial cells and dendritic cells but not 
in lymphocytes of the thymus (8, 9). In fact, isolated thymic 
interdigitating cells actually produce TXA2 (33), while lym- 
phocytes including thymocytes show negligible cyclooxygenase 
activity (34, 35). These results strongly suggest that TXA2 
works as a stromal cell-derived endogenous paracrine signal 
in the thymus and is involved in thymocyte maturation and 
selection. Because prostanoids including TXA2 are synthe- 
sized and released only upon cell stimulation  and TXA2 is 
a very unstable compound with a half life of 30 s under phys- 
iological conditions, we expect that it acts on lymphocytes 
only in close vicinity to or in direct contact with cells stimu- 
lated  to  produce  TXA2.  Such  a  property  of the  TXA2/ 
TXA2  receptor  system  fits  very  well  with  the  proposed 
character of the thymic microenvironment. It is already known 
that  other signals such as those acting on the CD3-T cell 
receptor complex (23),  the Fas antigen  (36, 37),  and inte- 
grins (38) are also involved in T  cell maturation  and selec- 
tion. Thus, different mechanisms appear to work at different 
stages  of these  processes  under  different  conditions.  The 
TXA2/TXA2  receptor  system may play  a  role  in  one or 
some of these stages,  and work independently or in combi- 
nation with other signals. Many growth signals serve as both 
positive and negative regulators of growth, dependent on the 
1828  Thromboxane  Az Receptor in Thymocytes situations.  Though  a  TXA2  agonist  induced  apoptosis in 
isolated  thymocyte  suspension,  TXA2  may  behave  as  a 
growth signal rather than as an apoptotic signal in the physi- 
ological context. Growth stimulatory activity of TXA2 has 
already been reported in aortic smooth muscle cells (17) and 
suggested for peripheral T cells (39). It remains to be deter- 
mined in what physiological context and at what develop- 
mental stage the TXA2/TXAz  receptor system acts in the 
thymus. TXA2 is synthesized through  sequential reactions 
by cyclooxygenase and TX synthase, and it has been shown 
that TIS10, a cyclooxygenase that can be induced by cytokines 
and growth factors, is highly expressed in the thymus of the 
neonatal mouse and disappears quickly after birth (40, 41). 
The precise role of the TXA2/TXA2  receptor system will 
be darified by determining the physiological stimuli required 
to evoke TXAz production in the thymus, and the present 
report should facilitate studies on its role for intrathymic T 
cell development. 
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